Biohaven acquires Priority Review Voucher
Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 …...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 …...
Cybrexa Therapeutics reports that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalex™-rucaparib). The...
Farmington-based immunotherapy startup CaroGen reports it has won a $1.4 million grant from the National Institutes of Health to accelerate development of its lead drug candidate, a potential...
Innovation to Impact at Yale announces a small grant competition for promising innovators committed to addressing substance abuse and addiction. Innovators will apply for one...
New Haven biotech Arvinas reports it has begun its first human trial on a groundbreaking drug that aims to fight prostate cancer by inducing the body...
Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the upcoming...
InveniAI® Corporation was featured in a Microsoft-sponsored series that showcases companies making a transformative impact in their industry with AI technology. Krishnan Nandabalan, Ph.D., President...
Alexion Pharmaceuticals and Zealand Pharma are collaborating to discover and develop novel peptide therapies for complement-mediated diseases. Peptides offer a number of advantages, including being...
Mostafa Analoui, Executive Director of Venture Development at the University of Connecticut, recently spoke to MetroHartford Alliance about what brought him to Connecticut, his role...
The Jackson Laboratory has signed a research agreement for up to $4.2 million with Sanofi to identify new targets to treat triple-negative breast cancer and...